Allopregnanolone and Dynamic GABA-A Receptor Plasticity in Selective Serotonin Reuptake Inhibitor Responsive Premenstrual Dysphoric Disorder.

A clinical trial, NCT06704594, aims to investigate neuroactive steroid dysfunction in premenstrual dysphoric disorder (PMDD) compared to healthy controls. The trial will assess the impact of SSRI treatment on GABAergic neuroactive steroid fluctuations, GABA-A receptor subunit expression, and neurosteroidogenic enzyme expression. The study is set to enroll 288 participants and is expected to be completed by July 1, 2029. The trial is led by Johns Hopkins University and focuses on understanding the underlying mechanisms of PMDD and SSRI treatment. [Extracted from the article]